October 02, 2014 4:15 AM ET

Biotechnology

Company Overview of Melinta Therapeutics, Inc.

Company Overview

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.

300 George Street

Suite 301

New Haven, CT 06511-6663

United States

Founded in 2000

42 Employees

Phone:

203-624-5606

Fax:

203-624-5627

Key Executives for Melinta Therapeutics, Inc.

Chief Executive Officer
Age: 50
Chief Financial Officer
Executive Vice President of Research and Development
Age: 54
Chief Commercial Officer
Senior Vice President of Corporate Development and Strategy
Compensation as of Fiscal Year 2014.

Melinta Therapeutics, Inc. Key Developments

Melinta Therapeutics and Hartford Hospital Announces Vitro Results from an Investigator-Sponsored Study

Melinta Therapeutics and Hartford Hospital announced in vitro results from an investigator-sponsored study that highlight delafloxacin's activity in low pH environments, which are characteristic of infection sites. Delafloxacin is an investigational fluoroquinolone under development for acute bacterial skin and skin structure infections and uncomplicated gonorrhea. In this study, which was conducted by Drs. Wonhee So, Jared Crandon and David Nicolau in the Center for Anti-Infective Research and Development at Hartford Hospital, urine samples were collected from patients suspected of having a urinary tract infection (UTI). Greater than 70% of these samples were acidic, with pH measured at or below 6.5. In all patient samples tested, delafloxacin was shown to be active against Escherichia coli and Klebsiella pneumoniae, two pathogens that are frequently associated with complicated UTIs. Importantly, in the acidic samples (pH 5.0-6.0), delafloxacin's activity was found to be one to threefold greater than in normal or basic samples. Complete results from this study are being presented at the 54th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an American Society for Microbiology meeting. ICAAC is being held September 5, 2014 - September 9, 2014 at the Walter E. Washington Convention Center in Washington, DC.

Melinta Therapeutics Announces Results of a Phase 1 Study of Delafloxacin

Melinta Therapeutics announced results of a Phase 1 study of delafloxacin, an investigational fluoroquinolone, in healthy adults that confirm a pharmacokinetic (PK) profile supportive of a single oral dose in the treatment of patients with uncomplicated gonorrhea. Specifically, results from this study of 20 healthy adults demonstrated that the mean time to peak plasma concentration following administration of a single 900mg dose of delafloxacin was approximately 1.4 hours, with a half-life of approximately 18 hours. Most common side effects were diarrhea, nausea and epistaxis (nosebleed). Delafloxacin is an investigational fluoroquinolone antibiotic with in vitro activity against both Gram negative and Gram positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Complete results from this study are being presented at the 54th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), an American Society for Microbiology meeting. ICAAC is being held September 5, 2014 - September 9, 2014 at the Walter E. Washington Convention Center in Washington, DC.

Melinta Therapeutics Appoints Christopher Kiritsy to the Board of Directors

Melinta Therapeutics announced the appointment of Christopher Kiritsy to the company’s Board of Directors. Mr. Kiritsy is currently president, chief executive officer and director of Arisaph Pharmaceuticals, Inc. Mr. Kiritsy also currently serves as chairman of the Board of Directors of Avaxia Biologics. Mr. Kiritsy has over two decades of business and technical experience from senior management positions in corporate management, finance, research and development, and business development. Under Mr. Kiritsy’s leadership, Arisaph has evolved into a clinical development enterprise with a rich research pipeline.

Similar Private Companies By Industry

Company Name Region
Bio Matrix United States
AdvanDx, Inc. United States
V-Clip Pharmaceuticals, Inc. United States
Neoantigenics, LLC United States
Eve Biomedical, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
February 10, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Melinta Therapeutics, Inc., please visit www.melinta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.